Qualitätsbericht 2021 49 | 72 Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor Erfassung der mittels ESD-Technik resezierten Tumoren im Gastrointestinaltrakt in den letzten 10 Jahren. Wie ist die Erfolgsrate? Welche Tumoren lassen sich mittels ESD behandeln? Komplikationsrate? Gastroenterologie PD Dr. med. Peter Netzer – Diagnostik der Laktoseintoleranz per Biopsie- basiertem Laktase-Schnelltest im klinischen Alltag Gastroenterologie PD Dr. med. Peter Netzer – Predictive value of ultrasonographic parameters for therapy response in Crohn’s disease and ulcerative colitis patients (TRUST BEYOND - 829) Gastroenterologie Prof. Dr. med. Frank Seibold AbbVie A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis (APD334-301) Gastroenterologie Prof. Dr. med. Frank Seibold ARENA A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn’s Disease (BMSTYK2CD-TYK2CD / IM011-023 (Lattice)) Gastroenterologie Prof. Dr. med. Frank Seibold Bristol Meyers Squibb A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod ad Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease (Ozanimod_RPC013201_Induction_MC + Ozanimod_RPC01-3203_Maintenance_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Celgene A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMBG_Lucent 2) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly A Phase 3, Multicenter, Long-Term, Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMAP_Lucent 3) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease (I6T-MC-AMAM_Vivid 1) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly
RkJQdWJsaXNoZXIy MzQxOTE=